Organovo (ONVO) Narrows Q4 Loss to 26c/Share

Organovo (AMEX: ONVO) reported Q4 EPS of ($0.26), versus ($1.17) reported last year. Revenue for the quarter came in at $215 million, versus $120 million reported last year.

"Organovo was able to continue our achievement of strong results in fiscal 2014," stated Keith Murphy, chief executive officer of Organovo. "We demonstrated the viability and utility of our 3D liver tissues and breast tumor disease model, expanded our partnerships, uplisted our common stock to the NYSE MKT, raised significant financing, and saw tremendous scientific results from our bioprinting efforts in a variety of tissue types. We will continue to focus in fiscal 2015 on executing our business plan and on striving to deliver long-term shareholder value."

For earnings history and earnings-related data on Organovo (ONVO) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c
• Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance